(NASDAQ:UNCY), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Unicycive and certain of its officers and/or directors have […]

(NASDAQ:ARGX), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors have engaged

(NYSE:CTO), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of CTO Realty Growth, Inc. (“CTO” or the “Company”) (NYSE: CTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CTO and certain of its officers and/or directors

(NASDAQ:LAZR), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Luminar Technologies, Inc. (“Luminar” or the “Company”) (NASDAQ: LAZR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Luminar and certain of its officers and/or directors have

(NasdaqGM:FLGT), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Fulgent and certain of its officers and/or directors have

(NasdaqGM:NPCE), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged

(NASDAQ:SDGR), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Schrodinger, Inc. (“Schrodinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Schrodinger and certain of its officers and/or directors have engaged

(NasdaqGM:TVTX), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Travere and certain of its officers and/or directors have

(NASDAQ:SMLR), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. (“Semler” or the “Company”) (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Semler and certain of its officers and/or directors have

(NASDAQ:META), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Meta Platforms, Inc. (“Meta” or the “Company”) (NASDAQ: META). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Meta and certain of its officers and/or directors have